Patient Management

Study Reveals Poor Outcomes for Post-Anti-CD38 Therapy

A retrospective cohort study analyzed patients with multiple myeloma (MM) refractory to anti-CD38 monoclonal antibody therapy, involving 663 patients, with a focus on those with triple class refractory...

CURATED BY: Laura J. Zitella,
MS, RN, ACNP-BC, AOCN

Laura J. Zitella

MS, RN, ACNP-BC, AOCN
Nurse Practitioner in Hematology/Oncology, University of California San Francisco

Patient Management Guidelines

Multiple Myeloma Guidelines

The International Myeloma Working Group, National Comprehensive Cancer Network (NCCN), and European Hematology Association and European Society for Medical Oncology (EHA-ESMO) worked to set forth guidelines that recommend the following diagnostic studies for multiple myeloma: serum and urine assessment for monoclonal protein, serum free light chain (FLC) assay, bone marrow aspiration and/or biopsy, and more.

EHA-ESMO Clinical Practice Guidelines

New guidelines provide key recommendations on the management of multiple myeloma (MM), and emerging treatment recommendations are provided for both newly diagnosed myeloma patients and patients with relapsed/refractory disease, plasma cell leukemia, solitary plasmacytoma, and smoldering myeloma

CURATED BY:
Larisa A. Gallo,
DMSc, PA-C

Guidelines

The Mayo Clinic provides information about mSMART: A clear and simple guide for treating patients with MM.

Articles

Study Highlights Increased COVID-19 Risks and Management Challenges for Multiple Myeloma Patients

Researchers assessed patients with multiple myeloma (MM) and their vulnerable to infections, including COVID-19, due to the disease and treatments compromising their immune system. This vulnerability is exacerbated by age,...

CURATED BY:
Jill N. Burke,
CNP, DipACLM

Study Examines Integrative Medicine in Plasma Cell Disorders: Reveals Top Practices and Quality of Life Impact

A study explored the use and efficacy of integrative medicine (IM) in individuals with plasma cell disorders (PCD), utilizing a 69-question survey conducted on HealthTree.org over three months. The survey...

CURATED BY:
Jill N. Burke,
CNP, DipACLM

Adverse Events of Novel Agents in Multiple Myeloma

This study focused on the evolution of treatment options for multiple myeloma, which now include immunomodulatory agents (IMiDs), proteasome inhibitors (PIs), monoclonal antibodies (mAbs), and a histone deacetylase inhibitor (HDACi)....

CURATED BY:
Jill N. Burke,
CNP, DipACLM

Lifestyle in Multiple Myeloma

The MASCOT cohort study explores the influence of physical activity and fitness on the quality of life, bone health, and fatigue in patients with multiple myeloma (MM). It evaluates patients...

CURATED BY:
Jill N. Burke,
CNP, DipACLM

Comprehensive Guide on Myeloma Diagnosis and Management

An informational website by the International Myeloma Foundation medical and editorial content team focuses on the diagnosis and management of myeloma, emphasizing early detection and individualized treatment approaches. It highlights...

CURATED BY:
Beth Faiman,
PhD, MSN, APRN-BC, AOCN, BMTCN, FAAN

IMS 2022 Session Highlights Myeloma Management and Nursing Role

Beth Faiman, a nurse practitioner at the Cleveland Clinic, gives an overview of a session she chaired at IMS 2022 that focused on challenges in myeloma patient management and the...

CURATED BY:
Beth Faiman,
PhD, MSN, APRN-BC, AOCN, BMTCN, FAAN